# Huichuang

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/huichuang

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.hcmedx.cn
- Total disclosed funding: $43M
- Latest round: Series B (May 31, 2024)
- Investors on record: 9

## About

Based in Beijing, China and established in 2016, Huichuang is a medical technology company that focuses on developing cranial nerve research and provides products includes portable NIRS (Near Infrared Spectroscopy) cerebral function imaging devices and cerebral function data analysis software. The founder Professor Daifa Wang has been research in the filed of near-infrared brain function for more than 20 years, and the R&D team graduated from California Institute of Technology and Tsinghua University. The company has undertaken three key R&D programs in China and owns more than 30 intellectual property rights including national invention and PCT patents. The company has reached academic and scientific cooperation with research institutions and hospitals, including the Institute of Automation of the Chinese Academy of Sciences, etc. In May 2024, it raised approximately CNY 100 million in a round of series B+ funding.

The company mainly researches and develops near-infrared brain function imaging equipment and data analysis software, and its products are divided into medical floor-standing type, portable type, and scientific research model. Specific products such as Nirscan-9000 brain imaging equipment, up to 157 channels and obtained China's medical device registration certificate, support for the whole brain area coverage, two-person simultaneous imaging of multiple brain areas and other functions. The company's products have been applied in more than 800 tertiary hospitals and scientific research units, such as 301 Hospital and Huashan Hospital.

The company generates revenue by providing fNIRS brain imaging devices and related services to medical institutions, research facilities, and other healthcare providers.

The company will use the series B+ funding raised in May 2024 to strengthen its position in the fNIRS market, advance clinical trials for transcranial photobiomodulation treatment of neurodegenerative diseases, and expand its team.

## Funding rounds

- Series B, May 31, 2024, $14M — Richen Capital, Peakview Capital
- Series B, Oct 31, 2023, $14M — Tsing-Yuan Capital, Addor Capital, Tao Capital, Haichuang Tiancheng Capital
- Series A, Jul 2, 2021, $15M — Lotus Lake Capital, Harmony Venture, Sunland Capital
- Series A, Sep 1, 2020 — Tsing-Yuan Capital

## Investors

- Tsing-Yuan Capital (https://capitalatlas.ai/funds/tsing-yuan-capital) — Series A, Series B
- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series A
- Harmony Venture (https://capitalatlas.ai/funds/harmony-venture) — Series A
- Sunland Capital — Series A
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series B
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series B
- Haichuang Tiancheng Capital (https://capitalatlas.ai/funds/haichuang-tiancheng-capital) — Series B
- Richen Capital (https://capitalatlas.ai/funds/richen-capital) — Series B
- Peakview Capital — Series B